Mikahail Blagoskloony Attack on Cancer
Mikhail Blagosklonny is an Oncology professor at the Rosewell Park Cancer Institute. He discovered the healing properties of Rapamycin. He believes it can be used to increase the life expectancy of cancer patients. He has conducted extensive research in the realm of cancer therapy. As Editor-in-Chief of Oncotarget, he conducted research on aging people. As a result, his contribution to the treatment of cancer is phenomenal.
What is Rapamycin?
Traditionally the drug was used for organ transplants. It would decrease the patient’s chances to reject the organ. In the early 1970’s it was discovered that the drug had tremendous immunosuppressive and antiproliferative properties. Although, the drug is an immunosuppressive drug it is less toxic toward the kidneys. Unlike other immunosuppressive drugs that ultimately leads to kidney failure.
Hemolytic-uremic syndrome is characterized as anemia, kidney failure, and low platelet count. The only cure for this disease is to get a kidney transplant. Without rapamycin, the new kidney will contract the disease. However, rapamycin reduces the chance of the kidney toxicity. Dr. Blagosklonny discovered the drugs ability to rejuvenate the immune system in elderly patients. The progress was noted after administering the influenza vaccine to them. This study also discovered the drug helped mice to live with tuberculosis. Although his discoveries are inconclusive in expanding human life, he continues to study.
Treatment of LAM
Rapamycin is a wonder drug that aids in the treatment of LAM patients. This disease is most noted for causing a rare lung disease in childbearing age women. However, rapamycin is the primary drug of choice to cure this disease. Its also used as a coronary stent covering. Rapamycin is applied to the stent after the balloon angioplasty is done. It’s the drug of choice because it doesn’t have to be reapplied often for it be effective.
Rapamycin treatment for Lupus
This drug is crucial in the treatment of Lupus Erythematosus. The disease has left patient’s resistance to immunosuppressant drugs. However, rapamycin unblocks mTORC1 in the patient. Thus, the patient body accepts the drug leading us closer to finding a cure.
Contributions to Oncology
Dr. Blagosklonny contributions to the field of Oncology is unprecedented. He’s not only a researcher but an expert in his field. He continues to seek out why cancer is prevalent among the elderly population. His quest is complex yet morally good. He seeks to treat the clients safely and effectively. His passion and dedication in oncology treatment encourage his students and peers to further his work. He is greatly respected by his students and colleagues
His goal is to not only treat patients with cancer but its to eradicate cancer cells. In hopes of finding a cure for cancer. He aspires to treat patients effectively without making them sick. He continues to conduct and gather research to cure cancer. He is determined to discover the connection between elderly people and cancer. His research is a great contribution to science. He desires to treat the patient in an economically feasible manner.